Sahnane, N.; Carnevali, I.; Formenti, G.; Casarin, J.; Facchi, S.; Bombelli, R.; Di Lauro, E.; Memoli, D.; Salvati, A.; Rizzo, F.;
et al. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Int. J. Mol. Sci. 2020, 21, 9708.
https://doi.org/10.3390/ijms21249708
AMA Style
Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F,
et al. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences. 2020; 21(24):9708.
https://doi.org/10.3390/ijms21249708
Chicago/Turabian Style
Sahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro, Domenico Memoli, Annamaria Salvati, Francesca Rizzo,
and et al. 2020. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor" International Journal of Molecular Sciences 21, no. 24: 9708.
https://doi.org/10.3390/ijms21249708
APA Style
Sahnane, N., Carnevali, I., Formenti, G., Casarin, J., Facchi, S., Bombelli, R., Di Lauro, E., Memoli, D., Salvati, A., Rizzo, F., Sessa, F., & Tibiletti, M. G.
(2020). BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences, 21(24), 9708.
https://doi.org/10.3390/ijms21249708
